Leerink Partnrs Increases Earnings Estimates for Bio-Techne

Bio-Techne Corp (NASDAQ:TECH) – Leerink Partnrs raised their Q4 2026 EPS estimates for Bio-Techne in a report released on Monday, October 13th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings of $0.51 per share for the quarter, up from their previous forecast of $0.50. The consensus estimate for Bio-Techne’s current full-year earnings is $1.67 per share. Leerink Partnrs also issued estimates for Bio-Techne’s Q2 2027 earnings at $0.46 EPS.

Bio-Techne (NASDAQ:TECH) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.50 by $0.03. The company had revenue of $316.96 million during the quarter, compared to the consensus estimate of $315.14 million. Bio-Techne had a net margin of 6.02% and a return on equity of 13.43%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.49 earnings per share.

Several other research firms have also commented on TECH. Evercore ISI increased their price objective on shares of Bio-Techne from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Royal Bank Of Canada raised shares of Bio-Techne from a “hold” rating to a “moderate buy” rating in a report on Wednesday, September 3rd. Stephens upgraded shares of Bio-Techne to a “strong-buy” rating and set a $65.00 target price on the stock in a research note on Tuesday, July 22nd. Citigroup upgraded shares of Bio-Techne from a “neutral” rating to a “buy” rating and increased their target price for the stock from $55.00 to $70.00 in a research note on Thursday, August 21st. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Bio-Techne in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $70.58.

Bio-Techne Trading Up 0.4%

NASDAQ:TECH opened at $61.86 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.46 and a quick ratio of 2.38. The company has a market cap of $9.63 billion, a PE ratio of 134.48, a PEG ratio of 3.93 and a beta of 1.48. Bio-Techne has a one year low of $46.01 and a one year high of $80.80. The firm has a 50-day moving average of $55.31 and a 200-day moving average of $52.61.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 18th were paid a dividend of $0.08 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.5%. Bio-Techne’s payout ratio is presently 69.57%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its position in Bio-Techne by 6.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,375,279 shares of the biotechnology company’s stock valued at $666,933,000 after acquiring an additional 721,012 shares during the period. Select Equity Group L.P. raised its holdings in shares of Bio-Techne by 129.8% during the first quarter. Select Equity Group L.P. now owns 5,366,003 shares of the biotechnology company’s stock valued at $314,609,000 after purchasing an additional 3,030,644 shares during the last quarter. Invesco Ltd. grew its position in Bio-Techne by 9.7% during the first quarter. Invesco Ltd. now owns 4,190,115 shares of the biotechnology company’s stock valued at $245,666,000 after buying an additional 369,651 shares during the period. Massachusetts Financial Services Co. MA grew its position in Bio-Techne by 18.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,025,409 shares of the biotechnology company’s stock valued at $177,380,000 after buying an additional 472,847 shares during the period. Finally, Champlain Investment Partners LLC grew its position in Bio-Techne by 8.9% during the second quarter. Champlain Investment Partners LLC now owns 2,665,684 shares of the biotechnology company’s stock valued at $137,149,000 after buying an additional 217,362 shares during the period. 98.95% of the stock is owned by hedge funds and other institutional investors.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.